YU86004A - Hfa-suspension formulation of an anhydrate - Google Patents

Hfa-suspension formulation of an anhydrate

Info

Publication number
YU86004A
YU86004A YU86004A YUP86004A YU86004A YU 86004 A YU86004 A YU 86004A YU 86004 A YU86004 A YU 86004A YU P86004 A YUP86004 A YU P86004A YU 86004 A YU86004 A YU 86004A
Authority
YU
Yugoslavia
Prior art keywords
anhydrate
hfa
suspension formulation
zoniatricyclo
hydroxydi
Prior art date
Application number
YU86004A
Other languages
Serbo-Croatian (sh)
Inventor
Christel Schmelzer
Original Assignee
Boehringer Ingelheim Pharma Gmbh. & Co.Kg.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma Gmbh. & Co.Kg. filed Critical Boehringer Ingelheim Pharma Gmbh. & Co.Kg.
Publication of YU86004A publication Critical patent/YU86004A/en
Publication of RS52481B publication Critical patent/RS52481B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics

Abstract

The invention relates to propellant formulations containing suspensions of a crystalline anhydrate of (1α,2á,4á,5α,7á)-7-[(hydroxydi-2-thienylacetyl)oxy]-9,9-dimethyl-3-oxa-9-zoniatricyclo[3.3.1.02,4]nonane bromide.
YU86004A 2002-03-28 2003-03-20 Hfa-suspension formulation of an anhydrate RS52481B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10214264A DE10214264A1 (en) 2002-03-28 2002-03-28 HFA suspension formulations of an anhydrate
PCT/EP2003/002899 WO2003082244A2 (en) 2002-03-28 2003-03-20 Hfa-suspension formulation of an anhydrate

Publications (2)

Publication Number Publication Date
YU86004A true YU86004A (en) 2006-08-17
RS52481B RS52481B (en) 2013-02-28

Family

ID=28050990

Country Status (21)

Country Link
EP (1) EP1492498A2 (en)
JP (1) JP5147158B2 (en)
KR (1) KR101005717B1 (en)
CN (1) CN1642525A (en)
AU (1) AU2003221509B2 (en)
BR (1) BR0308709A (en)
CA (1) CA2479638C (en)
DE (1) DE10214264A1 (en)
EA (1) EA008610B1 (en)
EC (1) ECSP045322A (en)
HR (1) HRP20040890A2 (en)
IL (1) IL163696A0 (en)
ME (1) ME00246B (en)
MX (1) MXPA04009338A (en)
NO (1) NO20044004L (en)
NZ (1) NZ536030A (en)
PL (1) PL371295A1 (en)
RS (1) RS52481B (en)
UA (1) UA79776C2 (en)
WO (1) WO2003082244A2 (en)
ZA (1) ZA200405637B (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2606549A1 (en) * 2005-05-02 2006-11-09 Boehringer Ingelheim International Gmbh Crystalline forms of tiotropium bromide
KR20080007656A (en) * 2005-05-02 2008-01-22 베링거 인겔하임 인터내셔날 게엠베하 Novel crystalline forms of tiotropium bromide
CA2763941A1 (en) * 2009-05-29 2010-12-02 Pearl Therapeutics, Inc. Compositions, methods & systems for respiratory delivery of two or more active agents
AU2015201037C1 (en) * 2009-05-29 2017-07-27 Pearl Therapeutics, Inc. Respiratory delivery of active agents
US8815258B2 (en) 2009-05-29 2014-08-26 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
BR112015022784B1 (en) 2013-03-15 2023-02-14 Pearl Therapeutics, Inc MICRONIZED CRYSTALLINE MATERIAL CONDITIONING METHOD AND CONDITIONING SYSTEMS
EP3515439B1 (en) * 2016-09-19 2021-12-15 Mexichem Fluor S.A. de C.V. Pharmaceutical composition comprising tiotropium bromide

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3931041C2 (en) * 1989-09-16 2000-04-06 Boehringer Ingelheim Kg Esters of thienyl carboxylic acids with amino alcohols, their quaternization products, processes for their preparation and medicaments containing them
CN1150890C (en) * 1998-08-04 2004-05-26 杰格研究股份公司 Medicinal aerosol formulations
GB0009605D0 (en) * 2000-04-18 2000-06-07 Glaxo Group Ltd Medicaments
GB0009606D0 (en) * 2000-04-18 2000-06-07 Glaxo Group Ltd Therapeutic combinations
GB0009592D0 (en) * 2000-04-18 2000-06-07 Glaxo Group Ltd Respiratory combinations
GB0009583D0 (en) * 2000-04-18 2000-06-07 Glaxo Group Ltd Respiratory formulations
DE10111058A1 (en) * 2001-03-08 2002-09-12 Boehringer Ingelheim Pharma New drug compositions based on anticholinergics and NK¶1¶ receptor antagonists
CA2436537C (en) * 2000-10-31 2009-05-26 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmaceutical compositions comprising tiotropium salts and antihistamines
DE10113366A1 (en) * 2001-03-20 2002-09-26 Boehringer Ingelheim Pharma Medicament for treating inflammatory or obstructive respiratory diseases, e.g. asthma or chronic obstructive pulmonary disease, containing synergistic combination of anticholinergic agent and endothelin antagonist

Also Published As

Publication number Publication date
IL163696A0 (en) 2005-12-18
AU2003221509A1 (en) 2003-10-13
BR0308709A (en) 2005-01-04
MXPA04009338A (en) 2005-01-25
NO20044004L (en) 2004-10-05
UA79776C2 (en) 2007-07-25
EP1492498A2 (en) 2005-01-05
NZ536030A (en) 2006-07-28
KR20040098022A (en) 2004-11-18
AU2003221509B2 (en) 2008-01-24
JP2005527550A (en) 2005-09-15
WO2003082244A2 (en) 2003-10-09
CA2479638C (en) 2011-01-04
EA008610B1 (en) 2007-06-29
MEP47308A (en) 2011-02-10
KR101005717B1 (en) 2011-01-05
JP5147158B2 (en) 2013-02-20
RS52481B (en) 2013-02-28
EA200401159A1 (en) 2005-04-28
ZA200405637B (en) 2005-07-27
DE10214264A1 (en) 2003-10-16
CN1642525A (en) 2005-07-20
WO2003082244A3 (en) 2004-02-05
CA2479638A1 (en) 2003-10-09
HRP20040890A2 (en) 2005-06-30
PL371295A1 (en) 2005-06-13
ECSP045322A (en) 2005-01-28
ME00246B (en) 2011-05-10

Similar Documents

Publication Publication Date Title
YU50903A (en) Method for producing the anticholinergic agent tiotropium bromide
TW200617007A (en) Crystalline anticholinergic and its use for preparing a pharmaceutical composition
YU27303A (en) Crystalline monohydrate, mehod for producing the same and the use thereof in the production of a medicament
PL392882A1 (en) New crystalline and amorphous form of triazole(4,5-D)pyrimidine compound
CA2296665A1 (en) Triazolo[4,5-d]pyrimidine derivatives as anti-thromobotic agents
TW200738672A (en) Intermediated for the preparation of 4,5-dihydro-pyrazolo [3,4-c] pyrid-2-ones
AU2003228770A1 (en) Substituted pyrazolopyrimidines
AU2002305143A1 (en) Pyrazolo'1,5-a!pyridine derivatives
CY1105543T1 (en) ANTICHOLINERGIC CONTAINING HFA SUSPENSION PREPARATIONS
WO2002048148A3 (en) Pyrazolopyridine derivatives
AU2002309038A1 (en) Compositions for transmucosal administration containing coenzyme Q as the active ingredient
MXPA04009162A (en) Piperidine or 8-aza-bicyclo[3.2.1]oct-3-yl derivatives useful as modulators of chemokine receptor activity (especially ccr5).
YU86004A (en) Hfa-suspension formulation of an anhydrate
AU1442297A (en) Piperidone tachykinin antagonists
AU5539899A (en) Novel triazolo(4,5-(d))pyrimidine compounds
AU8370498A (en) Novel pyrimidin derivatives
AU2002214467A1 (en) Novel compounds
WO2003033498A3 (en) A process for the treatment of ganciclovir intermediate n2-acetyl-9-(1, 3-diacetoxy-2-propoxymethyl) guanine
AU2001292423A1 (en) Formulations for reducing or eliminating toxicity of environmental hormones containing ursodeoxycholic acid
NZ509911A (en) Benzothieno[3,2-c]pyridines as alpha 2 antagonists
AU2003271057A1 (en) Novel crystals of triazaspiro(5.5)undecane derivative
AU2002217556A1 (en) Cholesterol biosynthesis inhibitors containing as the active ingredient tricyclic spiro compounds
AU3047897A (en) Endothelin antagonist